Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
27
10
2021
revised:
18
01
2022
accepted:
19
01
2022
pubmed:
11
3
2022
medline:
7
6
2022
entrez:
10
3
2022
Statut:
ppublish
Résumé
In December, 2020, two mRNA-based COVID-19 vaccines were authorised for use in the USA. We aimed to describe US surveillance data collected through the Vaccine Adverse Event Reporting System (VAERS), a passive system, and v-safe, a new active system, during the first 6 months of the US COVID-19 vaccination programme. In this observational study, we analysed data reported to VAERS and v-safe during Dec 14, 2020, to June 14, 2021. VAERS reports were categorised as non-serious, serious, or death. Reporting rates were calculated using numbers of COVID-19 doses administered as the denominator. We analysed v-safe survey reports from days 0-7 after vaccination for reactogenicity, severity (mild, moderate, or severe), and health impacts (ie, unable to perform normal daily activities, unable to work, or received care from a medical professional). During the study period, 298 792 852 doses of mRNA vaccines were administered in the USA. VAERS processed 340 522 reports: 313 499 (92·1%) were non-serious, 22 527 (6·6%) were serious (non-death), and 4496 (1·3%) were deaths. Over half of 7 914 583 v-safe participants self-reported local and systemic reactogenicity, more frequently after dose two (4 068 447 [71·7%] of 5 674 420 participants for local reactogenicity and 4 018 920 [70·8%] for systemic) than after dose one (4 644 989 [68·6%] of 6 775 515 participants for local reactogenicity and 3 573 429 [52·7%] for systemic). Injection-site pain (4 488 402 [66·2%] of 6 775 515 participants after dose one and 3 890 848 [68·6%] of 5 674 420 participants after dose two), fatigue (2 295 205 [33·9%] participants after dose one and 3 158 299 participants [55·7%] after dose two), and headache (1 831 471 [27·0%] participants after dose one and 2 623 721 [46·2%] participants after dose two) were commonly reported during days 0-7 following vaccination. Reactogenicity was reported most frequently the day after vaccination; most reactions were mild. More reports of being unable to work, do normal activities, or of seeking medical care occurred after dose two (1 821 421 [32·1%]) than after dose one (808 963 [11·9%]); less than 1% of participants reported seeking medical care after vaccination (56 647 [0·8%] after dose one and 53 077 [0·9%] after dose two). Safety data from more than 298 million doses of mRNA COVID-19 vaccine administered in the first 6 months of the US vaccination programme show that most reported adverse events were mild and short in duration. US Centers for Disease Control and Prevention.
Sections du résumé
BACKGROUND
In December, 2020, two mRNA-based COVID-19 vaccines were authorised for use in the USA. We aimed to describe US surveillance data collected through the Vaccine Adverse Event Reporting System (VAERS), a passive system, and v-safe, a new active system, during the first 6 months of the US COVID-19 vaccination programme.
METHODS
In this observational study, we analysed data reported to VAERS and v-safe during Dec 14, 2020, to June 14, 2021. VAERS reports were categorised as non-serious, serious, or death. Reporting rates were calculated using numbers of COVID-19 doses administered as the denominator. We analysed v-safe survey reports from days 0-7 after vaccination for reactogenicity, severity (mild, moderate, or severe), and health impacts (ie, unable to perform normal daily activities, unable to work, or received care from a medical professional).
FINDINGS
During the study period, 298 792 852 doses of mRNA vaccines were administered in the USA. VAERS processed 340 522 reports: 313 499 (92·1%) were non-serious, 22 527 (6·6%) were serious (non-death), and 4496 (1·3%) were deaths. Over half of 7 914 583 v-safe participants self-reported local and systemic reactogenicity, more frequently after dose two (4 068 447 [71·7%] of 5 674 420 participants for local reactogenicity and 4 018 920 [70·8%] for systemic) than after dose one (4 644 989 [68·6%] of 6 775 515 participants for local reactogenicity and 3 573 429 [52·7%] for systemic). Injection-site pain (4 488 402 [66·2%] of 6 775 515 participants after dose one and 3 890 848 [68·6%] of 5 674 420 participants after dose two), fatigue (2 295 205 [33·9%] participants after dose one and 3 158 299 participants [55·7%] after dose two), and headache (1 831 471 [27·0%] participants after dose one and 2 623 721 [46·2%] participants after dose two) were commonly reported during days 0-7 following vaccination. Reactogenicity was reported most frequently the day after vaccination; most reactions were mild. More reports of being unable to work, do normal activities, or of seeking medical care occurred after dose two (1 821 421 [32·1%]) than after dose one (808 963 [11·9%]); less than 1% of participants reported seeking medical care after vaccination (56 647 [0·8%] after dose one and 53 077 [0·9%] after dose two).
INTERPRETATION
Safety data from more than 298 million doses of mRNA COVID-19 vaccine administered in the first 6 months of the US vaccination programme show that most reported adverse events were mild and short in duration.
FUNDING
US Centers for Disease Control and Prevention.
Identifiants
pubmed: 35271805
pii: S1473-3099(22)00054-8
doi: 10.1016/S1473-3099(22)00054-8
pmc: PMC8901181
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Types de publication
Journal Article
Observational Study
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
802-812Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288
pubmed: 33630816
Clin Microbiol Rev. 2019 Mar 13;32(2):
pubmed: 30867162
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859
pubmed: 33301429
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
MMWR Morb Mortal Wkly Rep. 2021 Jul 09;70(27):977-982
pubmed: 34237049
J Med Internet Res. 2021 Jan 20;23(1):e24773
pubmed: 33470944
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099
pubmed: 34383735
JAMA. 2021 Mar 16;325(11):1101-1102
pubmed: 33576785
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Vaccine. 2015 Aug 26;33(36):4398-405
pubmed: 26209838
JAMA. 2021 Oct 12;326(14):1390-1399
pubmed: 34477808
JAMA. 2022 Jan 25;327(4):331-340
pubmed: 35076665
Clin Infect Dis. 2015 Sep 15;61(6):980-7
pubmed: 26021988
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
Lancet Infect Dis. 2010 May;10(5):338-49
pubmed: 20417416
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1653-1656
pubmed: 33382675
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):680-684
pubmed: 33956784
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Expert Rev Vaccines. 2019 Oct;18(10):1091-1101
pubmed: 31580725
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
BMC Med Res Methodol. 2019 Nov 15;19(1):208
pubmed: 31730474
Sci Rep. 2017 May 16;7(1):1956
pubmed: 28512303
Natl Vital Stat Rep. 2021 Jan;69(13):1-83
pubmed: 33541516
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656
pubmed: 33914723
Hum Vaccin Immunother. 2018;14(8):1963-1969
pubmed: 29580194
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520-1524
pubmed: 34710075
NPJ Vaccines. 2019 Sep 24;4:39
pubmed: 31583123
Vaccine. 2021 Mar 26;39(13):1812-1817
pubmed: 33678452
Vaccine. 2020 Feb 5;38(6):1476-1480
pubmed: 31883809